Tag: Exelixis
Ajinomoto and Exelixis to Jointly Develop Novel Antibody-drug Conjugates
Ajinomoto and Exelixis have signed a license agreement with to incorporate AJICAP®, Ajinomoto's proprietary site-specific bioconjugation and linker technologies, in the development of novel antibody-drug conjugate (ADC) programs being developed by Exelixis.
Initial Dose-Escalation of First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in...
An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop...
Exelixis and Swedish BioInvent International have entered into an option and license agreement focused on the identification and development of novel antibodies for use...
Novasep and Exelixis Sign Manufacturing Services Agreement for XB002
Novasep and Exelixis have signed a manufacturing services agreement for the cGMP clinical production of XB002 (previously known as ICON-2), a next-generation tissue factor-targeting...
Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates
Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates (ADCs) using Catalent's proprietary SMARTag®...
NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...
Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....
